• 1
    Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JK, Hamilton S, Vogelstein B. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990;50: 771722.
  • 2
    Goh HS, Chan CS, Khine K, Smith DR. p53 and the behaviour of colorectal cancer. Lancet 1994;344: 2334.
  • 3
    Hamelin R, Laurent-Puig P. p53 and cancers colorectaux. Pathol Biol (Paris) 1997;45: 87681.
  • 4
    Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, Girodet J, Salmon RJ, Thomas G. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994;106: 428.
  • 5
    Goh HS, Yao J, Smith DR. p53 point mutation and survival in colorectal cancer patients. Cancer Res 1995;55: 521721.
  • 6
    Medical Research Council Rectal Cancer Working Party. Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer. Lancet 1996;348: 16059.
  • 7
    Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997;336: 9807.
  • 8
    Raybaud-Diogene H, Fortin A, Morency R, Roy J, Monteil RA, Tetu B. Markers of radioresistance in squamous cell carcinomas of the head and neck: a clinicopathologic and immunohistochemical study. J Clin Oncol 1997;15: 10308.
  • 9
    Kotera H, Kusunoki M, Yanagi H, Yamamura T, Utsunomya J. A possible correlation between p53 overexpression and prognosis after radiotherapy combined surgery for rectal carcinoma. Int J Oncol 1997;10: 9715.
  • 10
    Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266: 80710.
  • 11
    Fan S, El-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ Jr, Magrath I, Kohn KW, O'Connor PM. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994;54: 582430.
  • 12
    O'Connor PM, Jackman J, Jondle D, Bhatia K, Magrath I, Kohn KW. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res 1993;53: 477680.
  • 13
    McIlwrath AJ, Vasey PA, Ross GM, Brown R. Cell cycle arrest and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res 1994;54: 371822.
  • 14
    Siles E, Villalobos M, Valenzuela MT, Nunez MI, Gordon A, McMillan TJ, Pedraza V, Ruiz de Almodovar JM. Relationship between p53 status and radiosensitivity in human tumour cell lines. Br J Cancer 1996;3: 5818.
  • 15
    Pirollo KF, Hao Z, Rait A, Ho CW, Chang EH. p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene 1997;14: 173546.
  • 16
    Brachman DG, Beckett M, Graves D, Haraf D, Vokes E, Weichselbaum RR. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res 1993;53: 36679.
  • 17
    Wilson GD, Richman PI, Dische S, Saunders MI, Robinson B, Daley FM, Ross DA. p53 status of head and neck cancer: relation to biological characteristics and outcome of radiotherapy. Br J Cancer 1995;71: 124852.
  • 18
    Jung M, Notario V, Dritschilo A. Mutations in the p53 gene in radiation-sensitive and -resistant human squamous carcinoma cells. Cancer Res 1992;52: 63903.
  • 19
    Bracey TS, Miller JC, Preece A, Paraskeva C. Gamma-radiation-induced apoptosis in human colorectal adenoma and carcinoma cell lines can occur in the absence of wild type p53. Oncogene 1995;10: 23916.
  • 20
    Slichenmyer WJ, Nelson WG, Slebos RJ, Kastan MB. Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res 1993;53: 41648.
  • 21
    Nehls O, Klump B, Holzmann K, Lammering G, Borchard F, Gruenagel HH, Gaco V, Gregor M, Porschen R. Influence of p53 status on prognosis in preoperatively irradiated rectal carcinoma. Cancer 1999;85: 25418.
  • 22
    Adell G, Sun XF, Stal O, Klintenberg C, Sjodahl R, Nordenskjold B. p53 status: an indicator for the effect of preoperative radiotherapy of rectal cancer. Radiother Oncol 1999;51: 16974.
  • 23
    Qiu H, Sirivongs P, Rothenberger M, Rothenberger DA, Garcia-Aguilar J. Molecular prognostic factors in rectal cancer treated by radiation and surgery. Dis Colon Rectum 2000; 43: 4519.
  • 24
    Rebischung C, Laurent-Puig P, Gerard JP, Thomas G, Hamelin R. Analyse des altérations génétiques du cancer du rectum: différences par rapport au cancer du colon. Gastroenterol Clin Biol 1998;22: 67987.
  • 25
    Vignati PV, Roberts PL. Pre-operative evaluation and post-operative surveillance for patients with colorectal carcinoma. Surg Clin North Am 1993;73: 6784.
  • 26
    Hermanek P, Hutter RVP, Sobin LH, Wagner G, Wittekind C. Classification of malignant tumors. Paris: Springer-Verlag, 1998.
  • 27
    Hamelin R, Jego N, Laurent-Puig P, Vidaud M, Thomas G. Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors. Oncogene 1993;8: 221320.
  • 28
    Fu CG, Tominaga O, Nagawa H, Nita ME, Masaki T, Ishimaru G, Higuchi Y, Tsuruo T, Muto T. Role of p53 and p21/WAF1 detection in patient selection for preoperative radiotherapy in rectal cancer patients. Dis Colon Rectum 1998;41: 6874.
  • 29
    Desai GR, Myerson RJ, Higashikubo R, Birnbaum E, Fleshman J, Fry R, Kodner I, Kucik N, Lacey D, Ribeiro M. Carcinoma of the rectum. Possible cellular predictors of metastatic potential and response to radiation therapy. Dis Colon Rectum 1996;39: 10906.
  • 30
    Spitz FR, Giacco GG, Hess K, Larry L, Rich TA, Janjan N, Cleary KR, Skibber JM. p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer. Clin Cancer Res, 1997;3: 168590.
  • 31
    Luna-Perez P, Arriola EL, Cuadra Y, Alvarado I, Quintero A. p53 protein overexpression and response to induction chemoradiation therapy in patients with locally advanced rectal adenocarcinoma. Ann Surg Oncol 1998;5: 2038.
  • 32
    Schwandner O, Schiedeck TH, Bruch HP, Duchrow M, Windhoevel U, Broll R. p53 and Bcl-2 as significant predictors of recurrence and survival in rectal cancer. Eur J Cancer 2000;36: 34856.
  • 33
    Wiggenraad R, Tamminga R, Blok P, Rouse R, Hermans J. The prognostic significance of p53 expression for survival and local control in rectal carcinoma treated with surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 1998;41: 2935.
  • 34
    Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clue to cancer etiology and molecular pathogenesis. Cancer Res 1999;54: 485578.
  • 35
    Moyret C, Theillet C, Laurent-Puig P, Moles JP, Thomas G, Hamelin R. Relative efficiency of denaturing gradient gel electrophoresis and single strand conformation polymorphism in the detection of mutations in exons 5 to 8 of the p53 gene. Oncogene 1994;9: 173943.